

higher than the as adjusted net tangible book value per share as of September 30, 2024. Therefore, if you purchase our common stock in this offering, you will pay a price per share of common stock that substantially exceeds our as adjusted net tangible book value per share immediately after this offering. Based on the assumed public offering price of \$33.70 per share, the last reported sale price of our common stock on Nasdaq on December 10, 2024, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, you will experience immediate dilution of \$23.45 per share, representing the difference between our as adjusted net tangible book value per share after this offering and the assumed public offering price per share. After this offering, we will also have outstanding options to purchase shares of our common stock. To the extent these outstanding options are exercised, there will be further dilution to investors in this offering. See the section titled "Dilution" for additional information. You may experience future dilution as a result of future equity offerings. To raise additional capital, we may in the future offer additional equity securities at prices that may not be the same as the price per share of common stock in this offering. We may sell shares of common stock or other equity securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing common stock or other securities in the future could have rights superior to existing shareholders. The price per share of common stock at which we sell additional shares of common stock, or convertible securities or other equity securities, in future transactions may be higher or lower than the price per share paid by investors in this offering. **A 12 Table of Contents** Our business could be affected by litigation, government investigations and enforcement actions. We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings that may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. Legal proceedings, government investigations and enforcement actions can be expensive and time-consuming. For example, on March 4, 2024, a complaint was filed in the Superior Court of the State of Delaware by ANI Pharmaceuticals, Inc. (ANI) naming us as defendant, seeking a declaratory judgement that a provision in an assignment and technology transfer agreement between us and ANI (formerly BioSante Pharmaceuticals, Inc.), dated November 15, 2010, obligates us to pay ANI 5% of worldwide net sales of cretostimogene. The court has most recently set a trial date of July 21, 2025. While we continue to believe the allegations are without merit and intend to vigorously defend this matter, such litigation could result in substantial costs and divert our management's attention from other business concerns, cause us reputational damage, negatively affect our stock price and result in monetary damages and future royalty obligations, if and to the extent cretostimogene receives regulatory approval. An adverse outcome resulting from any legal proceedings, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if such a proceeding, investigation or enforcement action is ultimately decided in our favor, the investigation and defense thereof could require substantial financial and management resources. **A 13 Table of Contents** **SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS** This prospectus contains or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained or incorporated in this prospectus, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical trials and preclinical studies for cretostimogene and any future product candidates, the timing and likelihood of regulatory filings and approvals for cretostimogene and any future product candidates, our ability to commercialize cretostimogene and any future product candidates, if approved, the pricing and reimbursement of cretostimogene and any future product candidates, if approved, the potential to develop future product candidates, the potential benefits of strategic collaborations and potential to enter into any future strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus also contains or incorporates by reference estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. In some cases, you can identify forward-looking statements by terms such as "anticipate," "expect," "believe," "contemplate," "continue," "could," "certain," "comay," "plan," "potential," "predict," "project," "should," "target" or "will" or the negative of these terms or other similar expressions. These forward-looking statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial and other trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus or in the applicable document incorporated by reference and are subject to a number of risks, uncertainties and assumptions described under the section titled "Risk Factors" elsewhere in this prospectus and in the sections titled "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Business" in our Annual Report and our Quarterly Report, as applicable, which are incorporated by reference in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained in this prospectus, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled "Where You Can Find More Information." In addition, statements that "we believe" and similarly qualified statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus or the applicable document incorporated by reference, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them. **A 14 Table of Contents** **MARKET AND INDUSTRY DATA** We obtained the industry, market and competitive position data used throughout this prospectus and the documents incorporated by reference in this prospectus from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. The content of these third-party sources, except to the extent specifically set forth in this prospectus and the documents incorporated by reference in this prospectus, does not constitute a portion of this prospectus or the documents incorporated by reference in this prospectus and is not incorporated herein or therein. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we are responsible for all of the disclosure contained in this prospectus and the documents incorporated by reference in this prospectus and we believe the industry, market and competitive position data included in this prospectus and the documents incorporated by reference in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled "Special Note Regarding Forward-Looking Statements" in this prospectus and in the section titled "Risk Factors" incorporated by reference in this prospectus from our Annual Report and our Quarterly Report. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. **A 15 Table of Contents** **USE OF PROCEEDS** We estimate that the net proceeds to us from this offering will be approximately \$230.6 million (or approximately \$268.6 million if the underwriters exercise their option to purchase additional shares from us in full), based on the assumed public offering price of \$33.70 per share, the last reported sale price of our common stock on Nasdaq on December 10, 2024, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive proceeds from the sale of the shares by the selling stockholder. The selling stockholder will bear the underwriting commissions and discounts, if any, attributable to their sale of our common stock, and we will bear the remaining expenses. Each \$1.00 increase or decrease in the assumed public offering price of \$33.70 per share, the last reported sale price of our common stock on December 10, 2024, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately \$6.9 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0A million shares in the number of shares of common stock offered by us would increase or decrease, as applicable, the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately \$31.7 million, assuming the assumed public offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing. We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of cretostimogene for the treatment of high-risk BCG-unresponsive NMIBC, including the completion of our BOND-003 Phase 3 clinical trial, submission of a BLA to the FDA as well as preparation for commercialization, subject to regulatory approval. We intend to use the remaining proceeds, if any, to fund the further research and development of cretostimogene for additional indications, including current and planned clinical trials, and for working capital and other general corporate purposes. We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities to in-license, acquire, or invest in complementary businesses, technologies, products or assets, including investments related to our supply chain. However, we have no current commitments or obligations to do so. We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations into the first half of 2028. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Additionally, our expected use of existing cash, cash equivalents and marketable securities and our net proceeds from this offering represent our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress and costs of our development activities, the status of and results from clinical trials, as well as the progress of any current or future collaborations that we may enter into with third parties for cretostimogene and any future product candidates, and the amount of cash used in our operations and any unforeseen cash needs as well as other factors described in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" incorporated by reference in this prospectus from our Annual Report and our Quarterly Report and "Special Note Regarding Forward-Looking Statements" in this prospectus. The net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, will not be sufficient to complete development in all potential indications of cretostimogene and any future product candidates, and after this offering, we will require substantial capital in order to advance cretostimogene and any future product candidates through clinical trials, regulatory approval and commercialization. Until such time, if ever, as we can generate substantial product **A 16 Table of Contents** revenue, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of those net proceeds. The timing and amount of our actual expenditures will be based on many factors, including the anticipated growth of our business. Pending the uses described above, we plan to invest the net proceeds in a variety of capital preservation instruments, including short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit and direct or guaranteed obligations of the United States. **A 17 Table of Contents** **DIVIDEND POLICY** We have never declared or paid any cash dividends on our capital stock. We currently intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, current and anticipated capital requirements, business prospects and other factors our board of directors deems relevant, and subject to applicable laws and the restrictions contained in any future financing instruments. **A 18 Table of Contents** **CAPITALIZATION** The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of September 30, 2024: **A 19 Table of Contents** **On an actual basis; and A 20 Table of Contents** **On an adjusted basis to give effect to our issuance and sale of 7,300,000 shares of our common stock in this offering at an assumed public offering price of \$33.70 per share, the last reported sale price of our common stock on Nasdaq on December 10, 2024, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.** The as adjusted information below is illustrative only, and our cash, cash equivalents and marketable securities and capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our financial statements and related notes and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" incorporated by reference in this prospectus from our Annual Report and our Quarterly Report and other financial information contained and incorporated by reference in this prospectus. **A 21 Table of Contents** **As of September 30, 2024: A 22 Table of Contents** **Actual A 23 Table of Contents** **As Adjusted(1) A 24 Table of Contents** **(in thousands, A 25 Table of Contents** **par value)** **A 26 Table of Contents** **share data (unaudited) A 27 Table of Contents** **Cash, cash equivalents and marketable securities A 28 Table of Contents** **\$ 540,710 A 29 Table of Contents** **\$ 771,289 A 30 Table of Contents** **Stockholders' equity (deficit): A 31 Table of Contents** **Common stock, \$0.001 per share; 700,000,000 shares authorized, 67,537,858 shares issued and outstanding, actual; 700,000,000 shares authorized, A 32 Table of Contents** **shares issued and outstanding, as adjusted A 33 Table of Contents** **Accumulated deficit A 34 Table of Contents** **(186,183) A 35 Table of Contents** **(\$ 186,183) A 36 Table of Contents** **Total stockholders' equity A 37 Table of Contents** **\$ 536,770 A 38 Table of Contents** **\$ 767,350 A 39 Table of Contents** **A 40 Table of Contents** **Total capitalization A 41 Table of Contents** **\$ 536,770 A 42 Table of Contents** **\$ 767,350 A 43 Table of Contents** **A 44 Table of Contents** **A 45 Table of Contents** **(1) Each \$1.00 increase or decrease in the assumed public offering price of \$33.70 per share, the last reported sale price of our common stock on Nasdaq on December 10, 2024, would increase or decrease, as applicable, the as adjusted amount of each of our cash, cash equivalents and marketable securities, additional paid-in capital, total stockholders' equity and total capitalization by approximately \$31.7 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive any proceeds from any sale of shares of our common stock in this offering by the selling stockholder; accordingly, there is no impact upon the as adjusted capitalization for these shares. If the underwriters' option to purchase additional shares is exercised in full, our as adjusted cash, cash equivalents and marketable securities, additional paid-in capital, total stockholders' equity and total capitalization as of September 30, 2024, would increase by approximately \$38.0 million. A 46 Table of Contents** **The number of shares of our common stock to be outstanding after this offering will be determined by the number of shares sold in this offering, the number of shares sold by the underwriters in their option to purchase additional shares, and the number of shares sold by the selling stockholder in its option to exercise its option to purchase additional shares in full, if any, less the number of shares repurchased by us in the open market or otherwise, if any, during the period from the date of this prospectus to the date of the offering.**

the right of stockholders to act by written consent without a meeting. Staggered Board of Directors Our bylaws provide that our board of directors is divided into three classes. The directors in each class serve for a three-year term, with one class being elected each year by our stockholders. This system of electing and A 26 Table of Contents removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. Removal of Directors Our certificate of incorporation and bylaws provide that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors. Stockholders Not Entitled to Cumulative Voting Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. Delaware Anti-Takeover Statute We are subject to SectionA 203 of the Delaware General Corporation Law, which prohibits persons deemed to be A interested stockholders A from engaging in a A business combination A with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business A combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an A interested stockholder A is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporationA voting stock. Generally, a A business combination A includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. Choice of Forum Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (the Court of Chancery) (or, in the event the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) A any derivative action or proceeding brought on our behalf; (ii) A any action asserting a claim of breach of a fiduciary duty by any of our directors, officers or stockholders to us or our stockholders; (iii) A any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or amended and restated bylaws; or (iv) A any action asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations A 27 Table of Contents thereunder. The enforceability of similar choice of forum provisions in other companiesA certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. Amendment of Charter and Bylaw Provisions The amendment of any of the above provisions, except for the provisions which do not allow for cumulative voting, would require approval by holders of at least two thirds of the voting power of all of the then outstanding shares of stock entitled to vote thereon, voting together as a single class. The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. Limitations of Liability and Indemnification Matters For a discussion of liability and indemnification, see the section titled A Executive CompensationA Limitations of Liability and Indemnification MattersA in our Annual Report, which is incorporated by reference in this prospectus. A 28 Table of Contents MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the IRS), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. This discussion is limited to Non-U.S. Holders that hold our common stock as a A capital asset A within the meaning of SectionA 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. HolderA particularly circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax provisions of the Code. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: A A A expatriates and former citizens or long-term residents of the United States; A A A persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; A A A banks, insurance companies and other financial institutions; A A A brokers, dealers or traders in securities; A A A controlled foreign corporations, A passive foreign investment companiesA and corporations that accumulate earnings to avoid U.S. federal income tax; A A A partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); A A A tax-exempt organizations or governmental organizations; A A A persons deemed to sell our common stock under the constructive sale provisions of the Code; A A A persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; A A A tax-qualified retirement plans; and A A A A qualified foreign pension fundsA as defined in SectionA 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE A 29 Table of Contents APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. Definition of a Non-U.S. Holder For purposes of this discussion, a A Non-U.S. HolderA is any beneficial owner of our common stock that is neither a A U.S. personA nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: A A A an individual who is a citizen or resident of the United States; A A A a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; A A A an estate, the income of which is subject to U.S. federal income tax regardless of its source; or A A A a trust that (i) A is subject to the primary supervision of a U.S. court and the control of one or more A United States personsA (within the meaning of SectionA 7701(a)(30) of the Code), or (ii) A has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. Distributions As described in the section titled A Dividend Policy, A we do not anticipate declaring or paying cash dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. HolderA A adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described in the subsection titled A Sale or Other Taxable DispositionA below. Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS FormA W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). This certification must be provided to us or our withholding agent before the payment of dividends and must be updated periodically. If a Non-U.S. Holder holds the stock through a financial institution or other agent, the Non-U.S. Holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. HolderA A conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment or fixed base in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. HolderA A conduct of a trade or business within the United States. A 30 Table of Contents Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates as if the Non-U.S. Holder were a resident of the United States. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. Sale or Other Taxable Disposition Subject to the discussion below of backup withholding and withholding under FATCA (defined below), a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: A A A the gain is effectively connected with the Non-U.S. HolderA A conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment or fixed base in the United States to which such gain is attributable); A A A the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or A A A our common stock constitutes a U.S. real property interest (USRPI) by reason of our status as a U.S. real property holding corporation (USRPHC) for U.S. federal income tax purposes. Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. A Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (unless an applicable income tax treaty provides for different treatment) on gain realized upon the sale or other taxable disposition of our common stock, which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, our common stock will not be a USRPI with respect to a Non-U.S. Holder if our common stock is A regularly traded, A as defined by applicable Treasury Regulations, on an established securities market, and such Non-U.S. Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. HolderA A holding period. Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. Information Reporting and Backup Withholding Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on our common stock paid to the Non-U.S. Holder. A 31 Table of Contents regardless of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will be subject to backup withholding or information reporting unless the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting. Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. HolderA A U.S. federal income tax liability, provided the required information is timely furnished to the IRS. Additional Withholding Tax on Payments Made to Foreign Accounts Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign Account Tax Compliance Act (FATCA)) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other disposition of our common stock paid to a A foreign financial institutionA or a A non-financial foreign entityA (each as defined in the Code), unless (i) A the foreign financial institution undertakes certain diligence and reporting obligations, (ii) A the non-financial foreign entity either certifies it does not have any A substantial United States ownersA (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (iii) A the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause (i) A above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain A specified United States personsA or A United States owned foreign entitiesA (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of stock on or after JanuaryA 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers (including applicable withholding agents) generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. There can be no assurance that final Treasury Regulations would provide an exemption from FATCA withholding for gross proceeds. Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.

rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. European Economic Area In relation to each Member State of the European Economic Area (each, a Relevant State), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the EU Prospectus Regulation (as defined below), except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the EU Prospectus Regulation: A A (i) to any legal entity which is a qualified investor as defined under the EU Prospectus Regulation; A A (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined under the EU Prospectus Regulation), subject to obtaining the prior consent of the representatives; or A A (iii) in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation, provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the EU Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the EU Prospectus Regulation. For the purposes of this provision, the expression an *offer* to the public in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase any shares, and the expression an *offer* to the public in relation to the shares in any Relevant State means Regulation (EU) 2017/1129 (as amended). United Kingdom Each underwriter has represented and agreed that: A A (i) A it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section A 21 of the Financial Services and Markets Act 2000 (the FSMA)) received by it in connection with the issue or sale of the shares in circumstances in which Section A 21(1) of the FSMA does not apply to us; and A A (ii) it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares in, from or otherwise involving the United Kingdom. A 38 Table of Contents No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: A A (i) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation (as defined below); A A (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or A A (iii) in any other circumstances falling within Section A 86 of the FSMA, provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Section A 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an *offer* to the public in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression an *offer* to the public in relation to the shares in the United Kingdom means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. This prospectus is only for distribution to and directed at: (i)A in the United Kingdom, persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order), and high net worth entities falling within Article 49(2)(a) to (d)A of the Order; (ii)A persons who are outside the United Kingdom; and (iii)A any other person to whom it can otherwise be lawfully distributed (all such persons together, Relevant Persons). Any investment or investment activity to which this prospectus relates is available only to and will be engaged in only with Relevant Persons, and any person who is not a Relevant Person should not rely on it. Hong Kong The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)A to *professional investors* as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance or (b)A in other circumstances which do not result in the document being a *prospectus* as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to *professional investors* as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. Japan The shares of common stock have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. A 25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person (as defined below) or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities A 39 Table of Contents in effect at the relevant time. For the purposes of this paragraph, *Japanese Person* means any person resident in Japan, including any corporation or other entity organized under the laws of Japan. Singapore This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares of common stock were not offered or sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i)A to an institutional investor (as defined in Section A 4A of the Securities and Futures Act (Chapter 289) of Singapore (as modified or amended from time to time, the SFA)) pursuant to Section A 274 of the SFA, (ii)A to a relevant person (as defined in Section A 275(2) of the SFA) pursuant to Section A 275(1) of the SFA, or any person pursuant to Section A 275(1A) of the SFA, and in accordance with the conditions specified in Section A 275 of the SFA, or (iii)A otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the shares of common stock are subscribed or purchased under Section A 275 of the SFA by a relevant person which is: A A (i) A a corporation (which is not an accredited investor (as defined in Section A 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or A A (ii) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor; securities or securities-based derivatives contracts (each term as defined in Section A 2(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section A 275 of the SFA except: A A (a) A to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section A 275(1A) or Section A 276(4)(i)(B) of the SFA; A A (b) A where no consideration is or will be given for the transfer; A A (c) A where the transfer is by operation of law; or A A (d) A as specified in Section A 276(7) of the SFA. Switzerland The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. Neither this prospectus nor any other offering or marketing material relating to us, the offering, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offering of shares will not be supervised by, the Swiss Financial Market Supervisory A 40 Table of Contents Authority FINMA, and the offering of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of the shares. Dubai International Financial Centre This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (the DFSA). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. Australia No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. Any offer in Australia of the shares may only be made to persons (Exempt Investors) who are *sophisticated investors* (within the meaning of section 708(8) of the Corporations Act), *professional investors* (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring the shares must observe such Australian on-sale restrictions. This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. Israel In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section A 15 of the Israeli Securities Law, 5728 - 1968, including if: (i)A the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the Addressed Investors); or (ii)A the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions (the Qualified Investors). The Qualified Investors shall not be taken into account in the count A 41 Table of Contents of the Addressed Investors and may be offered to purchase shares of common stock in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 - 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. Qualified Investors may have to submit written evidence that they meet the definitions set out in the First Addendum to the Israeli Securities Law, 5728 - 1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)A that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968 regarding Qualified Investors is applicable to it; (iii)A that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)A that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 - 1968: (a) for its own account; (b)A for investment purposes only; and (c)A not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 - 1968; and (v)A that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor's name, address and passport number or Israeli identification number. A 42 Table of Contents LEGAL MATTERS The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, New York, New York. The underwriters are being represented by Latham & Watkins LLP, San Diego, California. The selling stockholder is being represented by Goodwin Procter LLP, New York, New York. EXPERTS Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December A 31, 2023, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP's report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. We are subject to the information and periodic and current reporting requirements of the Exchange Act and, in accordance therewith, file periodic reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding companies that file electronically with it. Our periodic and current reports, proxy statements and other information are available at www.sec.gov. We also maintain a website at <https://cgoncology.com>. You may access our proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section A 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. We have included our website address in this prospectus solely as an inactive textual reference. A 43 Table of Contents INCORPORATION OF CERTAIN INFORMATION BY REFERENCE The SEC allows us to *incorporate by reference* information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. We incorporate by reference in this prospectus and the registration statement of which this prospectus form a part the information or documents listed below that we have filed with the SEC, and any future filings we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement: A A our Annual Report on Form 10-K for the year ended December A 31, 2023, filed with the SEC on March A 26, 2024; A A our Quarterly Reports on Form 10-Q for the three months ended March A 31, 2024, filed with the SEC on May A 9, 2024, the three months ended June A 30, 2024, filed with the SEC on August A 8, 2024, and the three months ended September A 30, 2024, filed with the SEC on November A 12, 2024; A A our Current Reports on Form 8-K (other than information furnished rather than filed), filed with the SEC on January A 30, 2024, February A 16, 2024, May A 3, 2024, May A 24, 2024 and December A 5, 2024; and A A the description of our common stock which is registered under Section A 12 of the Exchange Act, in our registration statement on Form 8-A, filed on January A 22, 2024, as updated by Exhibit 4.3 of our Annual Report on Form 10-K for the year ended December A 31, 2023, filed with the SEC on March A 26, 2024, including any amendments or reports filed for the purpose of updating such description. We will furnish at no cost to you, on written or oral request, a copy of any or all of the reports or documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to CG Oncology, Inc., 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618. You also may access these filings on our website at <https://cgoncology.com>. We do not incorporate the information on our website in this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference in this prospectus or any supplement to this prospectus). Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement

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xF2(03FK+WL4,0[!PPOBUHD>#9L0?O:4@O@#M8 MZI5A+@/IO[U:NMN55R-A/2E6,N1]P@8N?TY1)Y1#># M+,1L1QN^MZWVJ2%W>9(T/U,),KX1NQO)Z5WVY3UVAL~Y3*%#HESL57K4[M]!<79/ZA/[JY4P@P5ATK7]+ P4EQ\$)(Q,M)VQ=P!21;ST;+T95+!#%VJF95%M/9GD;LJ:19UD>38*H5HUV'DRLJ]F1NQ2. M[1^IV;9\$: [V\$10/AX&E76K1;EW?2-R>H"J7#CMFZIWW0/0J8M%P9?>Y6K;MO=4D.1Y,35B;%"5F/,"AQB"9-3,"9*9OL8*9<]3U2'8/WXURX>- M&S09VH4BED2!(JPD8(D,7:CI+3W2(Z,S#.V#K; <,>%K>R[5N]44L%+U%M0V5=L@G6@00 3Y'Q7;SL911YH:Y2H%?N0& 213KMH1MVJ611];K;O!BUZUVE(EE6!-0';L&#&[X1 M/3>1.9&1.90:/7L#6G18F"V\$%*%~"K2A;+4B=+D/5G4<70V/Q~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~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>76B GRN>O(M3#+Q)ZD5U\$NT*41@6C8VBY>7C@M+_(CPO>3-X+&HBZ~*XY+&M5&P@831 459B1Q95NWHX2KQFQJ&AH2S# =F1(1U<@%"Q#EF#!ME8M4@%9.B M#0@V8AL#DL74'IOALU-);K228JY*Q>5X(UKE3.Q);22J1ZD8^6+&6L=LZ M!N%*F8;R8LUE6-PL;C2A5R=0H*!& I'V#*Q@ \ 6770ZM= YVNO ZRXG@ M6U-1,1JUK+UT7+RGV/.!;B2(,Q,TKT>N90>KKBTX5/MYS8B?;T E! M9M5NSA@K7H)DK+&C69%Z/C/Z/W!^1XM?J Z>BJ VOEY=>@'@)>^O, R9G0 M=03'6S&MD%J7ERR3;R),&G4T+4%&+&37FW'Q5 JS3TJA#B4MF-@&4FVQ= MD- J0LG1- <,*IFTPL@,7T5-7&P)*6T@A!<@%U!>B@8HJM! M+ W>9;9M3WVJ9R~X8C51X1 L?J_>IL^+6.AW\$ZYK; @GAUJOKT.IKPN?IJR;YLM^Q5*4,7+K@#J%7#A%4*KV*!&J,V9H9A@>90>V6L-(>U+9'BNNNM' MIADX*49KV6-6G\$%\$!Q(EQBA0L?@RB-XD&QW20&HVO YGS<+2U Z#9A MD\$C ?W UEE,[NP3^0/VYUQZ+_,>R28N,J305@/&+R-FVRGE MAFM=!=!MIE&I!&P?BR>? F@2%K,VH"BLA!,>,&0S3YY018B,4- 3 M?1!>095X#N+U&%@() (.J;&A- R5E\O,NO)D.BJX,F;L+P8-5<+M69 1%*O@>C!M[21@G1]CDH,-^*#[!#U]=>6T/A/[3M]WK1UIF80U_ MO-EA=>^P@2/4Y4N7 KUPOAU2G9/G#S,>40'1%{A1F6FK=0R=, >1^Z S59%Q> [NNS]E63'4NY@OWDA8+4%&L9G9L@Y@ZU07, /JXP&5XF/C3B630 MZ5A]+? H=ZV!S;CJN+1<1FW7G*R11 M?Z<1FW7G*R11 MO>A4U X,YA@K4"!W>W+VRNADCE2,2)C>D@=U>-TB* Q#F'6W6KCY6U7KH MWK8TBTWV\$M-DV>ZVQ=K- 0;=37V*#HXC MY@/[LS];Y>7/10 G2; =Y+4%E(D)FEPMP8E>W>M1=4P2>26_ TQ>15M 1K56W5-/28+\$+2#1D)U.5%+J:@[L+)%=B55NTBPJ'>

X(3)(Y6%#I479X9'1H>E1\$.O-U8Y5# S>4(O:D0Y1'E',Y8CE+*W-E M)B-X03M8<6964%T.%O=E Y5C,Y3&Q8:C9V>"M/6758:8P.&U96DYL85A9
 M-3=&6%EQ.#5M+TX9%IV3#W=71*=>GY55%U-VU-(GA'1W9P)B-X03MS:51U MDM):T121FAWDHO)B-X03M*J+&C=0+T%+,"J5 M+SAI:U=V-6-F-4U.0.#9+W=!=!;T0K6E U3G K9\$YM-
 W%N-D\$Q36-10E5X2JN2F%W#94-D9Q56I0O4=D63%O M5%1T=FFJO:#)K2D%(9VXX;8'02S8W4#!FPO52JW1&M7=CA1\$@K M5\$0O3VEY+VQ!)B-
 X03M7>DHO2C,O2S8W4"J2V0P52O06M7=CEC9C5-#A@V M2RJW06!\$*U10-40Q=GIK=%HS.41.05%+3C%0W4P83!="#,S="J=KJ=RZ;W.: MB-X03LY<-\$)2C1*+THP=C5Z,F-
 CFJT:CA01"4:#45%+W#5C\$9B91!1DPK M)B-X03MP+SA217F1C-00>5E+31V+QV9G1*+THS+TUV-X039L+U+O1=K1 M5W8X05A*U"1\$+TJ)=CA01"4:#5+<2]N0F),8G1D1%)-B-
 X03M3-&E- M83AY87)1.65M*T@K\$0O4+DQ>3=506M).\$4Y+T13+S586%HO.5,O->680271F M-C10-4U.0.#9,6B]+02]M5"=M4=BM6,3)F+U5V)B-X03LVB,JY3%@K=5 X;4@K M9\$9F-5%
 ('.EF'>600=T%R60O M5-75U>BJ1WVF,5 X035F&TR!+TM+&VU4*P-2B2CM5G1+1VMJ M)B-X03MA2%,"6%9P4E5W%G06(9GAW+WE994C5X7TE,'=,->J1RZ;W.: MB-X03LY<-\$)2C1*+THP=C5Z,F-
 M5C\$9B95J=C9N+WE,6"MU1"4J1"11+J1+S+W#=(036X8;FB)X-B03M5%+<39;GM;GB)J-BX03M3+N=S=Z9C6859QAF975B5\$0Y168W M=FM/9DYGW8X07=R&8K5E,O.'L M.%
 Y.4@O=T%P)B-X03MD,6JF839D92M0,\$%Y<5D4U'!0.3EY6#-N"SE,+W=\$ M2U8Y=C= N-TA19EW9CAQ:UEV<@.Y.7E59B#=#G75D+S16*U O M)B-X03M!0W%8+VQCDM)2D0K)B-
 X03M3J0U50;3E36EEFJ1 M2'E*+V5%*S%3D(O4#A!1CEM=6\$0F594#=V, #O2 Y\$YY*WIF<@P096979GK M2\$P2K:7@S\$5VU4G(R4A0,3-U-
 S1Z+&V5F1+MG*V0U+W9R>E@O>4UB+VU3+1.7V,7M9@JW1&88Z=BX03L09EAM=B|K63,O3D,&RLQ3*8X03@=G0R=D101U13 M.%#&B#12#&UE)=J"JT M5%IV+T,%83=N968W-
 C@Q+SAJ1RU;W@R+W=<5AF,\$\$R,5AS)B-X03M3\$9&T'V44=0>D"4FE43\$D1%14,2M2&(086UV351W2"LK5S-4,VQX<6Y,350*S(S M.3.),T1Q9G,00C X361V,7):>5V.%\$+<5A/B-
 X03LX+S,Q-7(O-4-,+W12 M;GOO=%D+SET9IV4#A!9EAM=B|K63,O3D,&RLQ3*8O='%,!R'=C\$SCA,(G-2)B-X03M8*S%4/%R-%S=C/A480U,VXK*W9,M9B!)!0TUB+VUJ2&(O86Y)R,3-
 J."W0CEEE2K4F1F#;19'W8574O*U)M 3-N*RMV3F8O)B-X03M0TUB+VUJ2&(O86P5+S(Q1U=,6&8Q839R2#5'8L#K84UD=CEQ6+80E8AC-WHO04@Q M-7(O-4-,+W12)B-
 X03M3J="J4T&YB2CA/4T0046PO+W->5VY7Z6B)W3&8Y57-T.%F M>8"-M,5G=(=7EU+U6L+SA)B-X03LY5VY2ZB6JW3&8Y57-F1D@X-T8K4&EV-
 M064W2W%7*VE8+T%+,&1D2S@Q1#1L,1U7, TXK+S=R<E&5-50 M0V1S,T15=B1)B-X03M3V<Q\$P,T=L*V%0D,P8497@T4G50,UIX%5F>G 8-M"=M+34]-4\$R>F-
 K4"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z%AG4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03L4K&D8P6E"347'8C1C,\$PK:\$PO+T%+M=%!B)GJ5R5V%-K2U2,O,UDP9X9V\$056EAF,U+O+W#=>4T3LS3F1X8%P0,3,Q>=\$59G156#0X)M)-
 X03M,&EHX6G5,F8V=6X9V9D1"9F13+JR)W0W4-7,0-S9%W674&E#V11 M+TAX8VY4&1L9"MH3"X039T4&UZ+V=7+W#=>5-0.6HK9&DO2'AB94\$Y MJB-X03M(%>AG
 M4&1L9"MH3"!J4#9T4&UZ+T%1G8K<5=0:6HK9&DO2'AB94\$Y MJB-X03L5C,V178X02J,Q,"MB4#A!9U5E M8D8Y57 Y168G6&LO,T9E86HX4BMYF)2D9: M,%6M-4%O4#-9,SA-9D9(,=)B-
 X03M3V#;C10+VY9=G@X5V=14+EC%AG&1L4E8S;S\$W-D9U0G1V;611+G&63%9B,W111%(>O-T)S(B-X03LQ,W@X
 M569Z

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

M/\$^>28BC>OC)ME8Y 36C_Z9EDEL5HI_9XW72J_+R,S>_3CS+GMM=167^3 M[JGCM]454D=XH7M@C+RU@+LN(X=JD%53,EB>8ME8@G61_0M6KUK5_-IM
M107FIGA<^F?FST-1CPP/CP_/\$G@1U-4S766X1_?JYJ&_6Z,IGNAA)>T MHL2&_C>X+8(HE4Q9J_?O?ZT>H,S7^FJXM3U_32W:GDKHII,VFH/CN/K-M<#CX6<BYX/F?_
33UFSW4_1P2SU\$M%V_>AH66FM_@/FVWS-SVJ9BMOUE^_26/_B?D1DCPN..M77A2ZBC>RNV^?DIX2_81-36?F@Z4HWH>_?BOGHZ#HZN/NSN-W>96/_M6L6T7^_6?
2FMX10V4K4/M4W&HAT_<^>_?OT>P_1S77BMO^?^7NIA M^DMV15^UA,V&OJU^?705%P1BCP/HM+<S<_I@T#_?U9YCL?57K6EAJ M^N35KWVVKY ^OMT5-
_3DMW357_N#P<17QZ-2145_2UT1EHJF&B#BPOAD M#P#FCK8F-^FDDA>_M\$505LE_EJML-KGN=R/\$<\$.4^_3C>_66@>_P
LZONY?DQ1U1HJB-P3_9VDAKAT!_?SS<\$_MDP-B,(P5)P#AK3C@M43-3%PL7DZI2D9J@H6\$BSJ(C-D_&21073?_
MHHMGM_&^8H*IC1K<=<0/M/K/K4B,J^EN6A#AT/FF T43 & P4M&F MOH>J73^INFEBCV4U=F0=F13^KMC009NPWPV=YV-LC63T^=UN3P#F9(P>61 M,\$\$A3G9-
66YJZ5M1_DIX^BK&P-42M8&N_V151_01+T>MS M0.AC8/GF6Y>_81_&^4H,01_2STOP7K\$*<#JDN2/ZL/NFEN-^1>?K5U^?13EK M>O'LO^C.G4IAJH-RJU,8H0 LB?5,YP/+
ISOZEMUZYLV6DV_&_M1)67D9-50F<=IMTN-6YOC#CCAG@_R+>HYTOPK+405S<#HQB?>_?S M8=G,C&&^M4W^E_>B^74FR/5%<#DN>^IVOU=0.08SOX/_
_#S^HCTH10T42-7HUCB/XU5_R8UL M<FEECG_>IN/GAD@>_?I=6/2NC\$YSZR/U1^2GT% MZ\$XGSXN_H-9GM9=IM04+>W6MJAD9/H^S^I^KHZF94451#44I^+9(GA17
_>@C#OGK8S1_M60_37ZGUD>Z5M54OCW73_X_XG->_?<_&^%&H>_?M>_?JYJEELEOA,OR,WNH/1EXJXW2_18RFEICG^=^3_XT8^JDVJYVY2
MPPCK9FO(MOFWGP&N_E?#>_?OJZ<UD9U9/X_F9JXMSH9P_9U_1,1S>_?MCG@>_?X1^AW9W_XDM^_HTGJ<^CY9HJUZOUSKLM^_>_?14^GYPHR,8U/W22
M=>ND^@&G^)6E33NY101#Z1M5TH+03-T6JNHV_,DIY6R-SV9^?MW>JVN MS1LDNRH2%>_?34S-C#01DC@>090#2NW?4VG,>_?18^>SFQN-GET/FYI2+MC/G6/H?
3U+M4VE-LN,K)X?>_?H,02%>2W2X,B,C,T19S2_NN-MO)>_?M,1/0>9V9T-^?VIV051W8^TLO>PTV(1R15L1P5_5-WVTFN-^>_?OOEC MH:RLJ/N1A)>GMDC/PRX-
125EGUK<(Z12_-U7-SX1_M-01GYCD^M4B2=GK1KJ>_?XND@J:CSS/1Y/X%5^*_>_?SNMNBXH_MZRGHOHNE@_>_?1^269P3NECB_S<_?3+U/H201@_?1/2E9+>D>VK-X&AJ_GH
M1Z^JNS^&T4U3C-H2<_?Y,T@HXC@MUHW5=J#3H0IS7VULE^55,\$128^6 M@NR,DM)QOY^*OA/6BSWC913ZR920_>_?GCO M5^&Z4%>_?05U+4R0^=E_#_UYC/_?X_1YB
MB,X^G1_5=2G_RXEH-A^>_?L3ZV-HD,S^>_?NNG,U^?ILY^A^H^E?_>_?MMV1T53_ANUWMP^>_?E44,C,C_P^20/6/16H/60XVY7_45_X2W60-S4AY@NXL,1ZA
M1_>_?DZ^7K7RMKJH_R^S1U47^3_>_?CU/0A?T377_BP2UH1#>_?A>_?M1V1K52_2U>_?F1T1_&C9Z0?XKXMI_UZ=>_?S^T/972J1FV>ZUIMU M^F
356NCD@_>_?UT<@PXCFO6CUY6I^>_?1_H^GR_1L60I>_?0,5,4E+2S_M0JHHHIGU^?2IN1OD1_U,9/#)YEA-7-09J,9YK,5M934,M_H^K,B&GIV8WI9GAC1DX&2>_?
+5Y^>_?7HNM^>_?VSR_&GC@I>_?SK+XV4B,J05^6,MZ,P^KOEKA_0T/BZ2J8W1K^GD6Y>_?S_>_?HJZ>G15514004561S1G0#_6=>_?M%>_?V9G,0J,8D^JL55U1^=GU,>FTSO
W&DM8&YONAKO_631_NGK2@NW<5,C_M,Y3V0,>_?GDA<_?ZMH/H4,C^T1/1#^>_?9-57JK3D1#^>_?57RUP0^S^HAP^?9MQEISQX@C#M@01^>_?S6^?9CV@_?JAR
18/60G79WLM16H=D80%S^I_>_?9S^M7S^T@>_?<_?K0UN<_?9^D2Y6,S5^OMP>_?UE<_?XU^?4N@_?7B6C_HOD>_?R<_?MDJ^?47FG8^74G>_?XZGL-LJQ2W&6VE13_>_?FIE-
?^ZC0-RJ@Y109SY^>?D6,WNKMKZSS76_>_?P^2_>_?M9,J6NA;HS+C1_61,864X=P&10_>_?L#M^*F^S663^D3<_?36^W5@_?I+2A_2K1UQOB&BQ_>_?SSY4/Z>
<_?FOKFD^?H@_?CK@_?HEA_&MEM@U3HJN3-3B>_?CUK15K2_2U>_?F1T1_&C9Z0?XKXMI_UZ=>_?S^T/972J1FV>ZUIMU M^F
05W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>_?WD&EP&P>_?K/9E7-A,I_>_?2T4MHY>_?QCI^>_?RYOGC/3D2\$_01MXMW1PR>>_?O
_?Q5W6,UHFFV@6^R4S_MUHJ_>_?5,VKJ739J_>_?RT&D,PW>>_?XV2N-9_>_?YCVS26KJH01K5H_BF=>_?R_M-XKJSX7SA@AWGQV5_3_>_?6&AVO>_?ME
1N91761CZMG20/2^TK@_?B3D<_?O_MH&^2_>_?Y9%>_?Y6H1^=3>_?3W0H012^>_?N=T-T,Z>_?1_>_?993JVE90HVN8&MT>X>_?G_>_?XID,WN6=AG,AIRV,6V,S6VYR4Y1Z_5TLZ
MD#X.0_1CX00C_P#TM/_NDTFFG^KDD4-9351,VHH,F&HWY987A13@X_>_?M_>_?M,16T60E9W0HVN8>_?W>_?Y>_?Z=F_>_?GLW/V<_?C/G70Z,V26K6M^#V^H0N3-BHN-3,53>W_>_?T
_?X/6#_M7=>_?N3VY_0-Z&L1H^6/6FTBHK)X>_?K,1?>_?T_>_?S)31H5E_7TS^>_?MBAJ(FG^>_?EA>_?M@_?X_>_?Y^#Y9(YH,1)>_?9ZHGIM)>_?DR>%TNSVG
MGE7MD&J_>_?H=Z^#58Y8-5^>_?HIAEU>_?JATF^>_?MX<_?T&TGCZ2W^Y>_?YBF^>_?DL^&EK<_?K>_?20F20>_?M9^?WDXJ>_?Y73,M,O&T9R1@XMR,KB2UE=%K
M&PPZ6GTO<-_?4C_XJMSXCS_8W>_?M_P,W<_?4>_?5J,M>_?2A^?VYV30+1>_?ZB>_?POI^?>_?VNZ9_>_?P<_?W_>_?UDA9T/K5^_MFFZ-ENHJ^>_?C
?G>?#_?LAFFW5GLZUUMFT^>_?MISF1AD@%L%HCM146X_MR M^>_?>_?8_E_W100_OZEX813@_?A_MG0P_>_?B_MW1G>_?W^F@_?0%>_?AJ/PY_>_?YR7/1_>_?17-2T,6U-
?86R>_?VJK6,J_>_?T= M_>_?60W2JXW7>_?7>_?4/RZX,16=N_0S,P/3+WJ,FFJ_>_?HJHJ>_?D4DKJZ_>_?M_N^>

M,7-H-NDN#F-AW'N<L:7_0@+0,D.'+6/316E7E>/FOHISS0I=<-0%:I'M9U?*2-U5,JH*KB6=F06N!ORWA@GL651G93J6@VE6055Y05)<9-<-^M>YS@I'MR%CVX8W=ON@%F.
(Z^X13,BGB)V&%S.?BH*70M->H%74=6T4Q_K/WN#F-MGU#P JZ387HKXMI,I?^S=K*T-V3YY>IN@ANZ/3E?38G<-1H-0ZDN M%THFU#JAE#(TA@)=G=R7>P>K X^7@
@#D1G^T<7->9W81S7.6<(B M^S6 D-<W@5>7F5@DB>PD@:|->=0'BNSN?^B?_9DFL_TVX?69^ZGR36_M?2.9^@!JHIVIJ(A9-JLG_S0?X9?^6Y=UDUG?FW#ZS
MW51M_K=8.0<-6JY9B@X1A_NG(ZFCM6V5^C^A?19262_YG/MGIW9?N_MSSHO?NTUW9(B+Z_G?0VZ8K-ZZK(-)>JF?&YKJASFL&_2.3R?F?MMCH_SU&G1?6BTUKXGU-
3MBD?26SCL_4/MBM?>'R(MG2&ASFS#_KKBHVL2RN2N-LAK)=72N165D?I>C+G@#^@.RU MIZB#PZU_B*T+DH?R?29",B=15=1)EIG-K+36F?EIG8^..DP/W&S!O!O
M,C&=<IVS-C?WL-HPU?WT+LJ?OOZ?_Z3GNIW+>Y655G7EJD984<->MUMFL&F99_V2CZ1KKG=ON80YH_90DCJ2YC3NS>IVW8W?>3U_ZNU_M?R'ICWF6(O?C+
<HZE?^HJRGX8)OPZFS^R_9/8=7C>IWT?E<^G?N=^W?10_8Y6G6W!@>61Y=BE%?S_MW1L^_61?50T9M_T11AVE_IJBSASNNY?F8?3GENGM|XP4@Z4T074VBI
M,)JRZR?N618>^1-40XP6_R/D?30X?I+K\$4RJRD?&O UJV@II?35-#HO4 M5?WGFD+V=F@996K+20P?Y?VIBVSK99>_19M07?ZTUOAFW-DE M&E9?+
<8W@=<#PPI16>T2_ZD84%?NKB1D?Z?6%?>(ZCBEA10?&IRU#1&T->MFH?6?S/X?O/GDF?G?@>HEH?&BHF?H,C6L?K-H=TAK?P>_>B?1G-S M@DD/HY
<INSVP/ISJ162_6K?GNML_3D?#MY?P1D?/F?2H800?M8Y1L&%6L1UZ7Z00V?F=EE99?9UMWXFD22>F,_OEI?#L/F?X6FV?;2*S
M2NP?K?WV?&S!LABC_3?QBUSMS?>16?9P?1) (UY1R5AA?J?V7V1W?0_MLT?&J?TN?9J4E56_A?S=^X?G?U=H7V?0>U6S40L-NU1016498R?YTD_M?#SW20WYC?B+-
C&S>XZ?NFI?ZK1FEK?%Z?IC?NC?_MB?%H?#ARX?Y4=<"TW?>IUCI3?(>IS?R?>O5A?ZU?O?CJA?30N?I?>+
M7VZ&KDH?J?T0?I?OET>L<10LX30_R6ETS?S?WVWBKO=U?T1BFJ@?IY?>M?2<-?76?>T?IUK2-23S<^69L?I?J?L?W>IN?09W\$PNY?OS?#W0/MG.<I>=H-
M%?P?W<6?E?W?>19JN?LDDHW?T?CSP?D?2>L?W?6&1-IG?J?K?J?V?K?N?G?S?&MGNC?F?I?K?F?X?W?UG4L?K?CS?BBA?LEUK1?J?O?>?Y5_C?3RN?D-<
MO?018?GH?Z?N?C?L?LSZKU?_S?0?I?IOJK?G?P?FKW1?#RUV?O?C?X?H?G?M?Z?/2?L?1?&O?>624?/DK?3MN?L?P?8?F?W?SL?9?G?RC?/S?10?R?ISV?U?MM?U?57?BOU?/I?^?@D-
J?B?+?+OWIC?5H-74NCA?NNW?XEH?R/4?#?UL>HM84?C?130CNKJ?V?MOTM?MU?IB8?5TS?GM?<_&3D?<#F15?I?YH?1.B?*?J?HM?7.0?J?2T5?COBS?0?M?>UK6XF?J?1O?QGP?6G?
CB?B?8?4W?3?9-T?J?1?I?5?J?2?F?IO?/F?P?>M?Z?AC?X?9?Z?INGB?9-K?KDAHH?T?P?B?T?AH?6E?0?F?V?W?J?4?7A?%?V?H?
MHB?I?@?G4U5ENH?H?03?D?K?K?P?&OR?P?WV?7?P?O?_J?M?_K?A?7?K?6?D?B?3?K?O?>Z?MDM?D?@<?3?P?>=N?X?G?S?U?P?B?K?8?B?D?M?0?3?>PD?S?@C?X?B?H?>*E?O-
@V?W?>^4?F?>P?4?AC?>?7?T?>I?D?D?C?/..?M?Z?#?4?M?V?AT?&G?J?>2?4?D?V?G?N?Z?9?(&?O?>E?N?1?P?R?W?8?R?K?2?H?6?N?D?+>C?1?J?M?+?Y?9?M?N?V?
7?4?K?4?D?2?&L?2?^?M?S?>J?V?I?H?1?V?G?P?O?P?Z?H?R?N?S?U?K?>L?N?M?/0?M?R?I?Z?K?Z?>N?T?K?3?M?>Z?MDM?D?@<?3?P?>=N?X?G?S?U?P?B?K?8?B?D?M?0?3?>PD?S?@C?X?B?H?>*E?O-
?1?C?>?4?F?>P?4?AC?>?7?T?>M?N?D?T?2?<?N?O?>8?7?<?0?H?W?W?J?W?H?>I?V?N?D?M?9?4?C?>S?C?3?RN?D?<
M?0?1?8?G?H?Z?N?C?L?LSZKU?_S?0?I?IOJK?G?P?FKW1?#RUV?O?C?X?H?G?M?Z?/2?L?1?&O?>624?/DK?3MN?L?P?8?F?W?SL?9?G?RC?/S?10?R?ISV?U?MM?U?57?BOU?/I?^?@D-
J?B?+?+OWIC?5H-74NCA?NNW?XEH?R/4?#?UL>HM84?C?130CNKJ?V?MOTM?MU?IB8?5TS?GM?<_&3D?<#F15?I?YH?1.B?*?J?HM?7.0?J?2T5?COBS?0?M?>UK6XF?J?1O?QGP?6G?
CB?B?8?4W?3?9-T?J?1?I?5?J?2?F?IO?/F?P?>M?Z?AC?X?9?Z?INGB?9-K?KDAHH?T?P?B?T?AH?6E?0?F?V?W?J?4?7A?%?V?H?
MHB?I?@?G4U5ENH?H?03?D?K?K?P?&OR?P?WV?7?P?O?_J?M?_K?A?7?K?6?D?B?3?K?O?>Z?MDM?D?@<?3?P?>=N?X?G?S?U?P?B?K?8?B?D?M?0?3?>PD?S?@C?X?B?H?>*E?O-
@V?W?>^4?F?>P?4?AC?>?7?T?>M?N?D?T?2?<?N?O?>8?7?<?0?H?W?W?J?W?H?>I?V?N?D?M?9?4?C?>S?C?3?RN?D?<
M?0?1?8?G?H?Z?N?C?L?LSZKU?_S?0?I?IOJK?G?P?FKW1?#RUV?O?C?X?H?G?M?Z?/2?L?1?&O?>624?/DK?3MN?L?P?8?F?W?SL?9?G?RC?/S?10?R?ISV?U?MM?U?57?BOU?/I?^?@D-
J?B?+?+OWIC?5H-74NCA?NNW?XEH?R/4?#?UL>HM84?C?130CNKJ?V?MOTM?MU?IB8?5TS?GM?<_&3D?<#F15?I?YH?1.B?*?J?HM?7.0?J?2T5?COBS?0?M?>UK6XF?J?1O?QGP?6G?
CB?B?8?4W?3?9-T?J?1?I?5?J?2?F?IO?/F?P?>M?Z?AC?X?9?Z?INGB?9-K?KDAHH?T?P?B?T?AH?6E?0?F?V?W?J?4?7A?%?V?H?
MHB?I?@?G4U5ENH?H?03?D?K?K?P?&OR?P?WV?7?P?O?_J?M?_K?A?7?K?6?D?B?3?K?O?>Z?MDM?D?@<?3?P?>=N?X?G?S?U?P?B?K?8?B?D?M?0?3?>PD?S?@C?X?B?H?>*E?O-
@V?W?>^4?F?>P?4?AC?>?7?T?>M?N?D?T?2?<?N?O?>8?7?<?0?H?W?W?J?W?H

0GH%M%#|C MU4>K|ERDKU+Q-2T4U-)=M3>EQD70LC5,%#!FWK-2>LH^TA#_M.33EW.615#RNHY2>S250AGKVVY_H/0XJ,-(-.7C^U9:W(X6YZH-
2W.JX0N>J/WTMVJN\$2C>52+M6+IV#0%"Y5)8NG8,(RZN-LPI@TF)=E+&KGJCH+=JKA\$YHZ_?2W.JX1*Y5)8NG8,+
(7E4EBZ=@|PAJXVS"3C0EV4(NN>J/WTMVJN\$+GJCH+=JKA\$HWE4EBZ=@|PA>526+IV#0%"K&C,-*."790BZYZH_?2W.JX0N>J/WTMVJN\$2C>526+MIV#0%"Y5)8NG8,(N-
LPHTT)=E+&KGJCH+=JKA\$YHZ_?2W.JX1*Y5)8NG8,(7E4EBZ=@|PAJXVS"3C0EV4(NN>J/WTMVJN\$+GJCH+=JKA\$HWE4EBZ=@|PA>526+IV#0%"K&C,-*."790BZYZH_?

2W:JX0N>J>WTMVJN\$2C>526+IV#O M"-Y5)8NG8\.(N-LPHFT)=E'+KGJCH+-JKA'YZH_?2W:JX1*-Y5)8NG8\.(M7E4EBZ@C|PAJXVS^C30EV4(NN>J>WTMVJN\$+GICH+=JKA\$HWE4EBZ@|PA>M526+IV#O"SKC,"_?"90BZYZH_?2W:JX1ERSDGG\,ZM3CTO,C39T,JX1(UY M5)8NG8\.(J&4.EWU&EJ:149%-.?YPO>D2D7&3%&-,Z#@|F#9,|OJA@R M?3>?YFW(N,<-M5KBNB0|PYAR2U@1:K0)+R*PBZ75<D*3UC(8?TWGI@2M>I>WTMVJN\$+GICH+=JKA\$HWE4EBZ@|PA>M526+IV#O"SKC,M:>NRA@USU1^FNU5PA<142OH5(F&|ID1:731>+\$+R12O=-P=X0U->9A1HH

M21*77/5|[Z6|57%"SU1|^ENU5PB4,RJ2Q=-P=X00*I+%-T|WA#5QM%&FA+MLH1=<4?OLM5<(7/5|[Z6|57")10*I+%-T|WA#JDL73L>\$ 7&V84:\$NR
 MA%USU1|^ENU5PA<4?OLM5<(E&JDL73L>+\$+RJ2Q=-P=X0U<9A1H2|*M77/5|[Z6|57%"SU1|^ENU5PB4,RJ2Q=-P=X00*I+%-T|WA#5QM%&FA+LH1= M<4?
 OL M5<(7/5|[Z6|57")10*I+%-T|WA#JDL73L>\$ 7&V84:\$NR%US MU1|^ENU5PA<4?OLM5<(E&JDL73L>+\$+RJ20=-P=X0U<9A1H2|*77/5
 MU7Z6|57%"SU1|^ENU5PB4,RJ20=-P=X00*I+%-T|WA#5QM%&FA+LH1=<12?OLM5<(V2P2Z2>*2P2K2D2>*T6P6K2>*10*I+%-T|WA#A ZP2 246\$&P)

M+GJC]++-JKA\$HWE4EBZ-@[PA>526+IV#O%"KC,,-"790BZYZH_?2W>JX0N>M>J/WTMVIJN\$2C>526+IV#O%"Y5)8NG8.(-N-LPHTT)=E"+KGJC]++-JKA"YZ MH_?2W>JX1*-Y5)8NG8.(-7E4EBZ=@PA[XV\$C30EV4(NN>J/WTMVIJN\$+GCJ M)]+-JKA\$HWE4EBZ-@[PA>526+IV#O%"KC,,-"790BZYZH_?2W>JX0N>J/WMTMVIJN\$2C>526+IV#O%"Y5)8NG8.(-N-LPHTT)=E"+KGJC]++-JKA N1~^HB/M)]+-JKA\$HWE4EBZ-@[PA>52>+IV#O%"KC,,-"790X.+Y/Y4FSSCD&?N\$ MVFQ076?&{IDNCKLMM#L1#U1#01#U1#21#WTW&001#C9#EY#V1#2M7Y#06#7MZ MAG H123_+OKJ/WTMVIJN\$+GCJ L+-JKA\$HWE4EBZ-@[PA>526+IV#O%"KC,,-"790BZYZH_?2W>J

MO*1-%T!WA#5QM%&FA+LH1=<J401;M5<(75'Z6[57']10'11%T!WA"\MJD\73L>\$7+V84..\$NRA%USU1^ENU5PA<J401;M5<(E&JDL73L>\$+RJ
M20=-P=x=9A1H2I+\$77/5[Z6[57%\$U1^ENU5PA;RJ20=-P=x0+1%T!WA#5QM%&FA+LH1=<J401;M5<((D9A)M\J.M.GI=8E1=&CJN42,-526
M+IV%0/U*12BU12F,)-1G81->M-CBNL^WXHZNB*{P4,.3EJ+B6UM7Z*LYRP{?19WJ65X,;|-0T=9T*ZFIZ(F,7L,101;0;GV&\$
MZ-22LE&=1-99*VCHO(NMLI)3SB&TE9M4=A6F=A%~OS%5%FAZ&1S1+MT32/A-9D#A19E8Y1+^ZY~LH~G106%#HPS*IM+22 C7X00IG+GI:#Z2 MA" O_ PCW+;Y(I0-

=JWP1^S@N1_ODUVK? %S=JFNU,X,J,CGI_GON1^4JPAQ\$100+M1H4C4W\$5,J2R2<1PKE?7J*0LRGUB,+FGE1H3H2B1BC(SM)1%7:6E9
ML+&O>E991+S(FOZ<1^I<0W18?Y>ZHQ<7=4Z8WP#SN,I_ODUVK? *M+M1Q5ICK? =FV/1^R#DJS(3#Y>Y\$!@)N,I_ODUVK? %S=JFNU,X,J,CGI_GON1^8?+FZ?Y-
=JWP1^Y\$!@)M,N,I_ODUVK? %S=JFNU,X,J,CGI_GON1^8?+FZ?Y=JWP1^Y\$!@)N,I_ODUVK? %S=JFNU,X,J,CGI_GON1^8?%D)N,I_ODUVK? %S=JFNU,X,J,CGI_GON1^Y##FWZ"Y?P\$OS/D/E,<(3<1"SKR6U2T-1GQ1DQ?)>VC,7% M3(DGV,(X1E7:T,J)>*QPG?Z?C&K+2HDD7B5W3Y0)>^TOZB9,FZ?Y=JWP#)A.2:10!*)N*F9Z5END

MXC@%F=J=\$7\$1CGBIE!URVK#=>?B,YY^Y_ZI;HN=\$CM:QUO@M;\$5AUU1Y4@-B13AM7F3O3B0_MGRYNG^=37^M^7^T^P@X;21IN.?!=26ON1^8^?+FZ?HY-
=JWP^Y@+?@N;I_M-ODUVK%S@-FNUX_1;CG!@GON1^8^?+FZ?HY-=JWP^Y@+?@N;I_ODUVK?M%\$@-FNUX_1;CG!@GON1^8^?+FZ?HY-
=M3&6TCM.._M@_IGR>2F6\$@WS10\$VZEM6D4@9478V9K!YKX@VAL2^ZKJ!M@_WD?Z_M0J@_Y5-B)@_A2.1FPS9H_BD9@=OQGS@_Q5YR@_2F+15@Y\$1Q@Y\$!@?N;I_ODUVK?
%S@-FNUX_1;CG!@GON1^8^?+FZ?HY-=JWP^Y@+?@N;I_ODUVK?2%@-FNUX_1;CG!@GON1^8^?+FZ?HY-=IWPWMO@TOS7ZL1B2(MGVH+Y@_5@_8MURD1W_WU

MCBW69^4<3(7&D..W66&HW^,R+1.Q?M^((O9.|D%.Y/H%9)HYB,AE?WVEVV/V&761-0?2@GD>Y-AE,SXXZ,AY^*7Z+IJUZ5P+CKDOAU+6N^0E;&;3,S,RZ3&A^\$2A+G)L/A96
M15&0Y&7-7.5(I@PY2!@X-@A)JZW#L1;02\$V)2DK^"J!&I@0SQ^Y_P64E_M-2(B+^7+3F6/U>DN\$2!@P9!J)<(EV((R%&KPZJQAIR(R",JL8>B,AE
MD1>GNI@J#FWX+P64E_M-2(B+^7+3F6/U>DN\$2!@P9!J)<NR,A7-04R.M((O3W45!S,%B=71-ASW99&0.02")=NR,A7-04R.JL8>B,@OJK&O(C*947
M1H@Y^M@O_KTPER7_LC_71+A8N@W0.CKVM^*_5C-1>L0-1A5UC5/WD1D^P+TL MU^*07Z_MH_2@L3U)<(EV((#^2ZX1+LM1D^#7A1U5C^#WD1D^V_Y-59P1V@012(B/-14.M

OP6">U>DN\$2!={D9|J|};-{EV{!R%={KPZ|QAI|R|R%}>B, @#D1>GNH|#FW-MX+&Z027?}=-NR, @>DN\$2!={D9|NUX=58PJY|\$!>56, /&1+0&R|O3W45;S%: MB=71+A\$AW9&0|O2?}=-NR, A7, @>O|K+&C{#95*7H@Y@M=Q_MTEPB7, LC|D#)>^S*^B50^3^B02?|H|J>B, @ZG2B>?^6EV, ^{DV_M(1V-8)39D00|TU, |<=85|HIA9|R0FN2F7|J|Y?^T81_B2M92=A-1_UA_M0JDG6=J3+UVG^A(H3G02?|DN\$2!={D9|J|};-{EV{!MR%={KPZ|QAI|R|R%}>B, @#A2F2%>ZF_4-OP6|U>DN\$2!={D9|J|}}

M!AU5C#WD1D%=>58!T\$9J3!B!-14!OP!U>DN\$2!-D9!J!}<{EV!{R(%=KP!MZ!QJA|R!K!>B!>B!>B!>D1!GNH!#FWX+>H!H!H!J3!V0Z!>H!>H!>H!}<{3+EE!M!)}>66!H%{LP!E+>56!>1&0K3!B!J!-3!-2!>M-L!C!P!R!7A8G5Z2X1!+MV1D!KTEPB7!LC!{5V0!JK!&O!C!>P!ZP!QJA|R!R\$4R!(O M3W4M4!-OP!U>DN\$2!-D9!J!}<{EV!{R(%=KPZ!QJA|R!R(%=KPZ!QJA|R!K!>B!>B!>B!>D1!G!MNH!#FWX+>Z027!}>NR!,>A!>D!DN\$2!-D9!NUX!>58!P!J!Y!\$9!>56!>1&0!R!Q!R!O!W4!M5!S!%B!-7!+A\$NW9&0!O!Z7!}>NR!A!7!>B!>O!#JK!&O!C!C!9!\$7!H!@ MYM!^Q.KTEPB7!LC!{-7!+A\$NW9&0!KM!>56!>1&0!7AU5C#WD1D%>B!>T!U!>Z!B!>?@!ML3!J!}

<(EV1(R#5Z2X1+MV1D#7AU5C#WD1D%X=58P#Y9!3(B|-14~OPG) MU+DN\$21=D9!J|)<(EV1(R%#KPZJOA|R|R#JL8>B@#ID1>GNHJ#FWX+\$Z0
M27>#N@_U@DN\$21=D9#NUX=58P#Y9!3(B|+E#JLW>B@#ID1>GNHJ#FWX#MXGWJ#E#JXJ#J\$6MN#NH45G3H|)|#U%V5\$#(G#FIU.8ZV>MMHRE
MM9KR3|DX:027>=NR,@U@DN\$21=D9#NUX=58P#Y9!3(B|-3#MIU!S%;B=7+|A\$NW9&0.027>=NR,A7@#JL8>B@#O#JK&O#C#(C#9#7H|*
M@#YM~#O#KTEPB7|LC#71+A\$NW9&0KM|>56,|>1#Q7AU5C#WD1D%#B+TU%0<-MV_18G5Z2X1+MV1D&KTEPB7|LC#(5VO#IK&O#C#(C#PZJOA|R|R#F1%Z>ZBH,? M@#L3H|)

<(EV|(R#52Z2X1+MV1D*7AU5C#WD1D%X=58PJY\$9!3(B|-14-OP6M)U>DN\$2|-D9!J|)<(EV|(R%-KPZJQA|R(R"JL8>B,@HD1>GNHJ#FWX+\$Z
MO27")=NR,@U>DN\$2|-D9"NUX-58PJY\$9!>56,->1&04R(O3W45!S,%B=71-M+A\$NW9&0:027")=NR,A7:\JL8>B,@O#JK&O(C(*9\$7H|^@YM^"Q.KTEP
MB7,LC-71-ASW9&0KMP=56,->1&07AU5C#WD1D%W+B,JIU%0NR07|72JL8>B,ALY17>WD-10-H-V,J,C\$SYBA*

<&M?JH#M*TTFBS~OV*N@+0ZATQ@L+X'F&H=,8+.^*Y MBE6=6J=&F/&%*7@%H=0Z8P6%#S#4,F,%A? PJSJU13'G%"KP" T.H=,8+.^*Y
M/YAJ3'&PO@>859U:HICCSA5X1:4,F,%A? PU#IC@87P/1LZM44QYQ0J M-M#J3&+PO@>8:ATQ@L+X'F&H=6J*8/XH5> 6AU#IC@87P/0Z8P6%#S"K.M.K5%,><4*O
+0ZATQ@L+X'F&H=,8+.^*Y A5G5JB/,%7@%H=0Z8P6%#S#4,M.F,%A? PJSJU13'G%"KP" T.H=,8+.^*Y AJ3'&PO@>859U:HICCSA6%C\W
M-L7'Q/UG4JS1@C(RDT+1E1Y%G%+RE5<34N83IQ*4L*DNHG%V=L:DB_N/M#GQNP'T0J*RTB2~OV%G7Z-(R.J+3+T93KJ=%R4PRD)=AD>8M0Z8P6%#M\$S-
7>O15'1L5Z-XJAH,E7@%H=0Z8P6%#S#4,F,%A? Q6K6K5FF M-%7@%H=0Z8P6%#S#4,F,%A? PJSJU13'G%"KP" T.H=,8+.^*Y AJ3'&PO_M@>859U:HICCSA5X1:4,F,%A?
+PU#IC@87P/1LZM44QYQ0J M-J3&+PO_M@>8:ATQ@L+X'F&H=6J*8/XH5> 6AU#IC@87P/0Z8P6%#S"K.M.K5%,><4*O M
+0ZATQ@L+X'F&H=,8+.^*Y A5G5JB/,%7@%H=0Z8P6%#S#4,F,%A? PJSJU13'G%"KP" T.H=,8+.^*Y AJ3'&PO@>859U:HICCSA7F1_HB_US_D0V(GI_MJBZ=92.6Y3#)
(SML(C\$S+)%7DKZ(LW9*VC=U-Q6R)2%US%3CS%H54%3E&9R%,%S3Z#S#4,F,%A? Q2-MKMK5.NSLMVB(X#T#O+0+0ZATQ@L+X'F&H=,8+.^*Y*1LZM4FF,%7@%H=0Z8P
M6%#S#4,F,%A? PJSJU13'G%"KP" T.H=,8+.^*Y AJ3'&PO@>859U:HICCSA5AX1:4,F,%A? PU#IC@87P/1LZM44QYQ0J M-J3#SPO@>8:ATQ@L+X'F&H=,8+.^*Y XH5
6AU#IC@87P/0Z8P6%#S"K.M.K5%,><4*O +0ZATQ@L+X'F&H=,8+.^*Y A5G5JB/,%7@%H=0Z8P6%#S#4,F,%A? PJSJU13'G%"KP" M8A>2V2R_F+>ATQ@L+X'F/U-
'TRE1+3H4C(2:PQ*7-6J5V6.95H)M02-M34OJ81J+>T'X'A+7EOMDLEM#PBM2V5B9Q29E9="ES"27\$2)MPCZ2((019)),"W"%"#2.86LM%1HH"1L5M5V)=PRLUXR.
L_P%3#B&753M2#B%7\$17L1/6461NG#P#A#B7D1HICRHE@9C1)+D,PP1+<W\$D_MFROLC49UBQH,%(CZR#F(WF9*1BHD1C1U:LE><0:DIKF7Q3/E>->10C,B,0%
(2|R/MK+2J+ATGJAN\$ M(YEG*544MEL) PKT,4" M(9,3)&92151_80DCX0QDGDX,-S(B,AC,S_>M0A"34GF3S2&I=&+,61*2M+"C)1'U&IV=) #K,-NWV2IQ\$70\$SF1, QAM.PJ
MG77KU11&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)EX:U,&AOW_14Z_MRI>J/PV+(UZH) #,AR2J,X7,N0/(40>&M3_W1_#>0>5'MOX:8%ZJ4>AM@0Y/U-
<+CMW7D1JX7#>NO/(6@1#Q4ZRJ>J/PVPM-(UZH) #,AR2J,X7,N0/(40>&M3_W1_BUEZJ4>AM@07KU1M1^&V#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>
@07JCW-L'M)>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O-G67KU1^&V!>O5'0X:8.31S7M-X[>UY:ZCFN%QV(KR)3PUJ8&_?5.L07JCW-L"!>J?
PVP(05'0X:8%ZJ4>AM@0Y/U-<+CMW7D1JX7#>NO/(6@1#J_P5.L07JCW-L"!&*5'1(Y,7X8R)00R7-&+I57M-X[>UY:02633110X1,I&1'K'B)O'S,/#3#7#7XB9_A
MM@07KU11&V!#D_40>HYKA=>NZ@NAZB1<#F#M1Q4ZRJ>J/PV(M+UZH) #,AR2J,X7,N0/(40>&M3_W1_BUEZJ4>AM@07KU11M1^&V#D_40>HYKA=>NZ@T_F
F!OW>3K+UZH_#,>@07JCW-L'M)>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O-G67KU1^&V!>O5'0X:8.31S7M-X[>UY:ZCFN%QV(KR)3PUJ8&_?5'3K+UZH_#,>@07JCW-L"!
^>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O-BUEZJ4>AM@07KU11^&V!>D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7"X
M=UYHX:U,#?O-G67KU11^&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)M3PUJ8&_?5.L07JCW-L"!&W?KN=0263>9,VUDXFQH8B_0CSU'<+CMW7D_E
M*61R5C(FX*3:816M*^T SJ%V/>&M3S1-H46PC1:3Z3->J/PVP(04RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
PVP(GM3T^_X=9-05'0X:8%ZJ4>AM@0Y/U-<+CMW7D1JX7#>N_MOC/#61@_Q4ZRJ>J/PV(P+UZH) #,AR2J,X7,N0/(40>&MM3
W1_BUEZJ4>AM@07KU11&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G=KRE/J2)4X3KT,>B166,MD0R86NYW#
<{S3K}FO_E4S,4MM#>HE99.78M>J>J/PVP(<4RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
M5(VRM1:2.67KU11^&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)3PUJ8&_?5'3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G67
M07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G=RKE/J2)4X3KT,>B166,MD0R86NYW#
<{S3K}FO_E4S,4MM#>HE99.78M>J>J/PVP(<4RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
PVP(+UZH) #,AR2J,X7,N0/(40>&M3_W1_BUEZJ4>AM@07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_# M,>@07JCW-L"!>HYKA=>NZ@J1S7"X
M5KU11^&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)3PUJ8&_?5'3K+UZH_# M,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G67
M07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G=RKE/J2)4X3KT,>B166,MD0R86NYW#
<{S3K}FO_E4S,4MM#>HE99.78M>J>J/PVP(<4RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
M5(VRM1:2.67KU11^&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)3PUJ8&_?5'3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G67
M07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G=RKE/J2)4X3KT,>B166,MD0R86NYW#
<{S3K}FO_E4S,4MM#>HE99.78M>J>J/PVP(<4RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
PVP(+UZH) #,AR2J,X7,N0/(40>&M3_W1_BUEZJ4>AM@07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_# M,>@07JCW-L"!>HYKA=>NZ@J1S7"X
M5KU11^&V!>O5'0X:8.31S7X-[>UY:ZCFN%QV(KR)3PUJ8&_?5'3K+UZH_# M,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G67
M07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_#,>@07JCW-L"!>HYKA=>NZ@J1S7X-[>UY:HX:U,#?O^*G=RKE/J2)4X3KT,>B166,MD0R86NYW#
<{S3K}FO_E4S,4MM#>HE99.78M>J>J/PVP(<4RE\$R5:DF7QAGT=J,JP1L&@J1S7X-[>UY:W#PI=MYE,%G1,4V[57C32K/SGR.L07JCW-L"!>J?
PVP(+UZH) #,AR2J,X7,N0/(40>&M3_W1_BUEZJ4>AM@07KU11^&V!#D_40>HYKA=>NZ@T_F!OW_>3K+UZH_# M,>@07JCW-L"!>HYKA=>

Y:F53:#AT82|B4G4A3-4-2-7|0,\$-Y-%F(WA!.U5%8D900E)Y M;GAC971..\$5-51Y,\$@#X9D9%UEH>FI*8F\$V<"M7>G8V3G9P3W-S.#E)+U-3-M-VA%97!<!79%42!&%%,VIL;C5-V
M,G,O;~"UAG05=H05E61%50-W)C5D%4\$N-S00 M22|R5#1M;B1M>2MA=G-%-2M7,W5%5143E5,96!47)D46=C9E)4;B(F(WA!.M,T%,<38X859Y34DU-C5X-
6Y929SF0F(WA!.SED+TQ(+WSQ M-G(O,&QW+SE5F0Y9!2)JQ_39R+T%2F-0+M+U9,2&@Q2#@V4E0-C\$T.4X03FPX,%0F(WA!.W%6-2M7-W9.0DQ%7=%2CA.
M4W000T(Y,V8X5E16,Y8D=0>5-V.C-14)X151Y-C=O8C8W8U=0+U9,5R@M@O@N@QH+S9P6DQH,4@X-E F(WA!.WE0-C)R.C:S.#8#>EHS8B1J2C5E6\$QEQT# M2%0B;S\$EO5E=/3D)-
:\$%Q=6-73F3#54944T8G-9:553 M44(W>3-8\$-16C5B9'5J259S1*+>0C6P(WA!.TQD6(VB)B3#M+C-B9D-I<758351;5)K;00:50T=FA:418-TQB53-
M56E)R35ET4G1:5-/+W568TEK36=A M3D0X4U53=7->D@T8TDS=GDK6=6%F(WA!.W5865U9F010DY/6#U>E8U M-#U-
VA92DH4V4AS5U(P3#Q0E6YH16&5#4E%\$-S(F: M1=+D%34U8969W9F0U M35-+;S8K-#)F,35*3&F(WA!.S,Y>#P.1T16M0&T+S=0>#EY0UHK4UEJ5V9/371V<&,R
M;F142D(P(WA!.RM6 D3K4U5C0T#)G16E&E3 M0FEA5\$J>B1J4&U+8F\$U/FQ,+X-75B4D&L>GED+4#(F(WA!.VU1=7)X.TDV M,W)+%E44G9-
&T5X6%0F(WA!.WE*4WVQ0E=73FU0-7E;8S8K-M>E)U4E3C4J+4C129C1\$0V543S&58SUX3S4R-E!*>TUFIJ9M/E#>VYEDT8V9/14(F(WA!
M-S%U9DIX>DUK=7E<%M<2W,4H0>D0R,RJ53VU1>AV:69V8FV4>1\$-V=G M,&TQ3WA6.DMO,U=0TJ3B3IS9BM)DE9+W/B=%(Y6E\$F(WA!.U=485A9<3=& M55IR4"!-
(6'9VUEEJ)J6GE4#92-VTS3CEC=F5526GL<9H'U6-E)F9(DY3 M-45A&ES2WA3#)A57173VXK<61B-S@F(WA!.S@08D50\$U720S2%65&J
M;&5Z="S2-9G)Z44V66X06U%FA:8E=K1W-E6&O@D#1\$5Q@2\$995S=8M2!-13E";>C15S5FF(F(WA!.U1,%7%6A3UD1C6\$1%0VA-%HT9S1K14H=&A15"-
W5E58:7H1@R<4-3 M2VM43(T-T,THE9\$03"LV,#9+868X=79-9&AD4TTF(WA!.VE33&1>E1& M5U5Q,&=!VQ054YE4%-14-D*TY'1E9L>I" W5+2TAC,G-U;2M4.54Q1WDQ
M92@X93Y&Y68C)8,5A96%E0UAN044F(WA!.VYN%=>52DA-FM'-M%Z=TEO M9756,%560F7)8D)>V-G3&YY,&J#6#51,"!S96,\$Q,*V16=DQS>AR84YC M2DG-
5=>DS44,(F(WA!.TYC,TY1975X-41)2P8M3AS669L2\$=>5'DV M*VU*>#J\$P59&6G1,&E->W456,VIE+&UN,7\$V=>#OQ M-2=M-1%((V0V1&),&E32\$JF,DY>#9*,#9A86-Z4TLF(WA!
M.V9Y.FY35%D-<%!5=71644PV8UAR34-864V-<)&5%24VY564Q0.%Q,C->M+W=1,55T6YM.5-&96-
0834%56G1K4U34W9%&MK9S351F.%F(WA!.V00=6S90C%0=E5L+U%95D=0 M-5=Z0E&F,&1\$&5H04V106\$434XYY=>4-%H9W9V8Y521S3=%345N,W\$Y
M-&S90Y+Q#4*EC+T0383\$F(WA!.V-T>D8X07EV,D)4G(004 F M,FO,FOEHR46Q=78U6EA-5%,K:6Q,71Q56%K%>675-67%05G&C4F(WA!
M.V62'1L,&1F1DAY3%C6%1W,CAY:4PW4V1/%14>7EF-T,-5\$Q,4O-"X051&5"J350K4G8X07%4268K&EAE9C@Q6691 M>2V>>JS47@X9D00<68F(WA!.RMY2TDQ2"!-4Q7-
%60-5%H8RMJ05%F\$&K4C@O=T4+W="U56<69M5%7E7 M-#)=5AG6F8Y52R26%V2/40K5VQ-E9A86!>VF0W1FAU<IE-59%,F60 M3)>T4D-2.5IC=DEF=61Z-C1/0V-
225(U*UH05V1U9898FPQ+S%0B.P-S.F-M.%\$Q5GEV*U5S+S@W(T(F(WA!.RMP,B1)0V1G+>V086Q9<6QX-U=8-93,T5S M%"J3L%0041V5-07%79&UB,U!(368F(WA!
M.TYN;FM>4Y>4U71T1-5D5517B3TAM=C=K1&B.&T0E3'3-V2C=10S)V,&ML=&DU->IW27)Q>R=S53-%5P M431(4VY8-%A,E1Z2%)
(148Q=>MB94F(WA!.V183#A)8CE8C*8G-6.G56 M0F=G479+&Q0E)1<MK1F9T061!%-9\$4X45)S,SSH*U9R965+,W9.471R
M2S5L47E#,W9*1W1P148F(WA!.T9)17%496TP5/5\$W/Y045J,TY9J+>4C5"8M1D+M+TU>4EQ=>72JY,&IG,FYB5V1/358F(WA!.M:W98,7DS4W18:6J:4U+>UH,V51C,R-
C0K1%U2SA15\$MZ-HK6Q5Z55H M3G13-3-K:4D5P17EQ>6T8C1Y95A-VD01E,F(WA!.VQD=75234-1M9%,8C0W&Q,YMP9G=X6Y,A,DE5T5Y\$0F5143-
#5\$U7455061.F0V,#4F(WA!.W5G5%5,1%5F3U9K9E)K,W5N M="M,-DER, VU03\$QB,U5C%69U3955M:60">4>YBLR4E51361Q,69T66MV+N%&#E0*%">-3EU-VE4>G193F,S
M0W196(F(WA!.U5D,C9C-EA3-TQ/F=>5T9Y-T9E*U%954E)G,Z1U>2%6-F4M9T65-*>VY-T5Y8G16E-X\$125611 M=712-71,&414-VZ>&%85FY02VAL=>DT-%9%=>VU-
4HF(WA!.V=Y16U-%*M+U598D%C=40%9-F97%*06E->CE5D1Y0T1-26TR, HK8D9K2G403FMC96%G-M-FE15TMY9&9G,6%73B19H9C=3-4J70E\$F(WA!.TA141)2E9A2-91%Q-S
S!C M8W5S+W569CIV<31V4C9F,D7E85',S<%#02TP2VPR M,U8R,W)F1%>K>&H6# F(WA!.T@W935R3358+V5\$-T9321&-6Q8GCDT,C-W
M>F1A2T9J:FOQ6,&IT2F5E=6-J3\$E&231Q5D5-%>Q2V1X=>6\$U2\$1(1&K0G8A9>C>VE9BVF(WA!.S(0,71F,7!3E"!6XT+2D-9C%E3%1)=5\$M-7E!-%/3EAS9*8Q34DX-
2MS9DUT-T1,8W1D=&T7%T,E=65,2T9-3%N.3149(F(WA!.VMM65%*DY6 M+W=>FLO-6@W8BQ1Q2%61)62M%*S-58,C"-%7=1951A,EEQ-T958G)(-TA2 M;2,R4%"!4FM-
9C1T,FK#A8,#5Y=F%/45-Z1W5M>C/%V9-9-%#>71-2G1,&XY M-#Z4#8X5E6I+1FEP4R(>UDP935/3\$P,39#0SAL6"E">#8SE0X17-%9FA6FME M,2J+=E1%E-261%,%W
M;V9C49(2E1)1T1-M1D>#981T533%F(WA!.W0,C%F8V8V,EIE8G,W4C5-M4BM8,6M5\$5V161K=69Q,%3#3THK3%/%>SIE,UL(4E2D9I,C,V,&E99RJ7
M854S,TE-579,>FY#2S\$F(WA!.V1A,4AV+TPY>S3M3W3EV+U9R5C19<7164F=3-M4UA%35V1D6J-D>C9358R-G)K,WJ93AP2U(4%49\$W994K9E5)3\$45&4-1.4M)+U5A4UU-
&IP>D>Y26609W\$W4DI>2F9+1VAW>%(K-M-<733V82&Y1S1J-<%53,F-+>M206)3-1F+T%#>G(F(WA!.VAZ230Y,U%8 M,W5+T%#9#)A4T%\$26LQ,%5,%
T5GEE65);>E45M-5%3&Y995-240Y M;F1A4F17"17/04D4RE-24%54,\$U3U&T7.1&5#540314Y+6YP2U503\$Y1D-K:8E9K255.3V@W-SH>38F(WA!
M.S-92DHR2#0W,%0K-4JZ6GE%66LX5758,RJW03U5%V,&V&H,S-7,K:FT9#13 M5# USFA0U,%U(275)>#1427E19W-E03-Q5SP),P@AT9G(F(WA!.S00>1N6#0K M-S-
U3&HP4%IS:4)5.%EV-%5%RJ2&Q0V56F5V5V8V2S&F.G(K3V)53WI>F%U631D>G-2-6XK M-C5F,S5Q4V578CDT,VU8>7AO+W3=>9C56A7,T-S=TH&1DIM,TJX<%1R:U(R
M!D1DQX,3-235+17%1S,1%5/EDX'S,Y6D4P6F6U6H7Y,3E\$36,F(WA!.M1W52621(V06&1,1%>B/W0D,K,BIM
M+V0K<=%V8G940DUT90P->854A->#N9*S988C-88F(WA!.TUL3#)G,5DU M4UEW6J2D5E763D909#1.9*E1H,6,P->CA!-C-7,"!W1%-.+WID,V0X05)\$<2U M->DPO045,-
DPK8CDS-FY6Y%Y,+P%F5-M050W,VFTY5P2/\$2+1&2-F-T5-5D0-&J%P/0GDU:U085U5D:#9C94F(WA!.M:RJ-%*P%W-F,%92+SA\$7)VBX,X7HV>S9P8C)D>F)Y4VQ,A,T4P8T%G
M4E=5%U,&EZ34-1+4X5R5V2XV2F1%OF(WA!.W1,5F5Y3T3E+&6H0,G0U53%A M-3 V>G174*Q,S%6/E)E0FVH,31H,DQ!1BM-6%H1F%F6A=&V>F5(-G
Y8U1&>L"LV3T-<54UA\$9E9B>4E2Z4EAO=>F4S1R2D1%87,4,61P,M2750,D-TU9P26%76C9)-=Y1-EX-2X="M=>EA84THF(WA!.T9L,716:64V
M9V54T4XT-TUA"2T)U764-4%406DHP,%4X56,X,&V251,&AB479C97Q3GAP,M,&M:4Y(4-%43959F7E474(K>C1.0\$5F(WA!.VFT=RM448W,5%U9E5T6D-5
M-<%666C%V=BMJ-E1U4V4&33&A-5&A0,5,W4M%433AY-4P(F(WA!.T9G6U,69S%SEW67A4Y4%09WFA=>G(V4E4A# M3V8Y-W51GIAH,%9*EIM=>6H4TLX4BHK
M:6Y,VHF(WA!.T)>W9F9X59FHT3EE6D->S5H2&F-EQ0G=G9-(CA19G5M:G9,0U,-,U1Z2F51,T1V1TPE,65-4%Y-C%85A9S941\$41<#-034\$F(WA!
M.VU#8C0U6#AF-BM8H5&IM0E)W=TA3S%2*9B9,G90>C@P5V11,1T9V9AT-<%=M>CY,F=K55-X45A295545452F2),S%V5%4P1D9%3F\$F(WA!.U9R,&Y14DE-1M3U-
Q,%B,WHV*U14-STT,WE2&DT-35Y,G183'U,GH19W5D1VYT6&IU3T)F,V45N37EW=>ID2\$EK3!7=7AQ5T0%,F(F(WA!.V\$W6E9X44EO>FLR.=737)J M:FAT,3(W<5 V=F-
R=&896X)3-X(9,CDT34M2=3-P<70Y&Y,44%9S%D-3 R-U,W;714235%99 U9DFTF(WA!.RJ7=7"2U97(7A1,1H,S%3%PSDF(WF(WA!.W-V14MX=W(S1#-D+V0K\$16 M-65,4U9:1
<#E1K614F1Y,UE90FM(0U1X)3V1-7S-3753J!->08T8Y-S4F(WA!.W-V9G3-E<3R(C,P.DU4\$U6C6"LFWV1,W%>C5-VET
M=F5L=>E,W1Z2&586%U<#PF=GJ56J55FQ083->4YA,\$K3\$8W2\$M:4" M3BMP>7-2>7A-63A0<"(-#5#2FU-7\$F(WA!.TIV,\$K+U@O04EW=RJW1\$IP
M8VY0,C,A,718-351F2E54Y1K1W@R2W5X5D5A"J6V8H2Y"!J0D5-3V9-&M245X>G4X2P,F,D=845E>FYV-6Y,G,3N:30S>E V.97%-W1E8P9CDT M=GH-
C@F(WA!.U9F=8R,S56-%6%>3AD,FO1R4=L>C9F666Z9->89G)M<6-6W56%>&S02%DQ1S1V\$%2,&2T8S9E9-1E1A,FTN-7=Y1V1R3HF(WA!
M.T):>S29S,S66HJ4E9G5,->4F93)U0S7AD4B0M,6E1I3%>J+TXR3%-B1T-6&4=N,4M,,750,VPT,7=62LF(WA!.T9:G,A0DA# M12M)=7):G-#3W1"2#DS6C4P=39H13,U,C-&
&5Z<%&1S,0S<Q-69R5T2E4M7-U,4T2M4-5&83&E3S2CA9GHF(WA!.VPS5EED)9G6H4T4Y>E04U&M87ERDAS,%6-8C-44TPV8GEC,%PX1FI"WEF=>A04E-
19D,0<Q\$#U=73#U@M67V4,Y=4>C9(4%E,+&F(WA!.U8R659U4DTP4VER>DMA279Q>#P,S,0K4-&M=R33=55-
0<"JW0V).>#5C1G,Q-W!K1W1,3U%,=4%671,8C9U>6HQ5FUG M,&AQ1UDF(WA!.VAM-\$M0<# X0V%>95\$O&+PY1HY,%F81U%>0U4F(WA!.VI,-6Q,-<1/M.&=M=G(O,7-14U-
44)S1D@V<71-F>#5W-1'E-E965%4&29S%P43H5U-M153V1D9C5V45E(U4T-74T-%M4,F5E64)E56-B4T4U2545B5CA#3C993U15%U@K>#DO=T-H5&HW4#)O
M4TXK951Q4O4R>DAV-DLF(WA!.SDP+S5P,G,P,UK5-5W:35!<#T9T8T2F&T M25%Y<7E005%35T%P559P6\$IZ+TY23F)F-T0U>SG0F(WA!.M-W;R>30T3&7-
553>7&6D103\$WY1D1-%@T>%P-DAR9VYK,5514V1&P,1&P#>M1D1\$1J3-9(1G1),30U,&4F(WA!.VE+&H6K5451FTS345D>DBP
M4'2;4IY6EAI,D5H,5984E45-87%2049C9V5595)-4E1A1TE3C=% M:Y0>4F(WA!.UDU=E82\$5I-2J&6G)E46+&S5Q3E,->U1"2GEQ>7(X27)4 M:CEM=>N17DQ3CAX+W-
F9BM\$=>551,(2U\$SBLF(WA!.W0,G3V14V1\$3F)-S1D1P369B,41+845P,V99-61Y,7591VED+V0,4J,M1,S5%,24=X+WI+3+U=S+WAZ-XD0=T-7<% X07!
(=>F(WA!.RMO9504H%W+M+>#W=Q96F9Y50-7 O-7 0->I7,V34Q-1%7-34Q,2-1X-61H,6-L4%6-A8C4Y,U%F9E9W1-0B@F(WA!.TDX>B!>H0,E,W+V5O+S0T,IF
M-1:9B134G,O-%645D,O,G-V9CEG+U5Z+VMS%Z5"IP<&9R9"J,6L,61+>W24P+&V6D>=53AF>C(F(WA!.UAU,%S2#9L+VMR5"JW03=O-T,M,;RM/
M4\$TS+TQ42"PC(O,%S9Q\$@04%IE+S->W1F4L+P+LW>D3K-6C6K,6P-5%V=V4\$V15,M,%#F(WA!.U3162&M28FDS=6-K:6L1Y341D M1SE15D0F(WA!.S:K2%O),S:75FE)-E-
24UH3CE9+TXW4611-G(K>79Z4S@A M64-65E6DT,DUR%482-1E4U#,->F25E%K14)46H2\$97F5*&T(F(WA!.M:W,%#5V260995=D-<%E3Z3F5Z15-1-
=%S-T%K04-Z,%#Q0<4T2I2C X M=TQ)55-#9M74S%6&U,4TDY57-4U4UFD(WA!.VXX-&AE54DR M*S9S47\$Y&46#46\$W8B9R1J"1G5B1P,U5V1&9,9W5B0G)K>C(R
M;U)T3V=J5U,0.5-1.6U25V1X2SAL-F(WA!.W8,F1C2DUB*W)>693.5IV M-4MO-TW%Y,<3C%1\$Y,V,DV9<4%&L6U=GH1V0R26MNN\$H1-3A2-&UQ M-
S%5\$QU34,04Y7&K8K9ASV9G,VAO-S8P-V=3C5-87,>E273A3F<5-L2"JE1U)>6Q,TEK,M:RLY8W"44562510-%E,FY&247>F(WA!.T1U,D59-,%Y451J M34MA<\$1.7%
(1\$Y1F0U%4U9243-Q3E)22G5"5#92&QL" M&4S)W+UHY*W!N1\$U3U40->M(5G)Y-F-Y3F\$T\$0DJK:GEC-7DQ5G%N<#O3G-4-W9N>"3&AR:#A,8C-D
M:3E4&50-5U-86G,G(WA!.T4-4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW8W4%>E7F0S-P3E1D=5%,5DY2=51K:FUH M9&L*U
F(WA!.VUW1T7D5C18,7V947H5K21-4J4A600E-%&HF(WA!.S%U240V9S,U=AL362E1D1F1P,"Q,MF5-/M-B1T1SHO,G
0.1#5#(B1-93DK51,33)H*UA,3%IV4U04E)H<6,E0F M-2M-SA+>2MT65@+K+T\$A6UDF(WA!.S@Q,C%J2&-0-5AV,VUE95--F-2,6QK15-7-E1R39%9)1VIQ
M-E-E,GA-#A13D-1V>2T10,4B@O7-E1U+8Q,VLX)B461R*V<4/E7H569-545U56Q8B-FI31D1V&A,1UH#,THD
M,V10,S-3C&1C,V1/4#4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW8W4%>E7F0S-P3E1D=5%,5DY2=51K:FUH M9&L*U
F(WA!.VUW1T7D5C18,7V947H5K21-4J4A600E-%&HF(WA!.S%U240V9S,U=AL362E1D1F1P,"Q,MF5-/M-B1T1SHO,G
0.1#5#(B1-93DK51,33)H*UA,3%IV4U04E)H<6,E0F M-2M-SA+>2MT65@+K+T\$A6UDF(WA!.S@Q,C%J2&-0-5AV,VUE95--F-2,6QK15-7-E1R39%9)1VIQ
M-E-E,GA-#A13D-1V>2T10,4B@O7-E1U+8Q,VLX)B461R*V<4/E7H569-545U56Q8B-FI31D1V&A,1UH#,THD
M,V10,S-3C&1C,V1/4#4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW8W4%>E7F0S-P3E1D=5%,5DY2=51K:FUH M9&L*U
F(WA!.VUW1T7D5C18,7V947H5K21-4J4A600E-%&HF(WA!.S%U240V9S,U=AL362E1D1F1P,"Q,MF5-/M-B1T1SHO,G
0.1#5#(B1-93DK51,33)H*UA,3%IV4U04E)H<6,E0F M-2M-SA+>2MT65@+K+T\$A6UDF(WA!.S@Q,C%J2&-0-5AV,VUE95--F-2,6QK15-7-E1R39%9)1VIQ
M-E-E,GA-#A13D-1V>2T10,4B@O7-E1U+8Q,VLX)B461R*V<4/E7H569-545U56Q8B-FI31D1V&A,1UH#,THD
M,V10,S-3C&1C,V1/4#4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW8W4%>E7F0S-P3E1D=5%,5DY2=51K:FUH M9&L*U
F(WA!.VUW1T7D5C18,7V947H5K21-4J4A600E-%&HF(WA!.S%U240V9S,U=AL362E1D1F1P,"Q,MF5-/M-B1T1SHO,G
0.1#5#(B1-93DK51,33)H*UA,3%IV4U04E)H<6,E0F M-2M-SA+>2MT65@+K+T\$A6UDF(WA!.S@Q,C%J2&-0-5AV,VUE95--F-2,6QK15-7-E1R39%9)1VIQ
M-E-E,GA-#A13D-1V>2T10,4B@O7-E1U+8Q,VLX)B461R*V<4/E7H569-545U56Q8B-FI31D1V&A,1UH#,THD
M,V10,S-3C&1C,V1/4#4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW8W4%>E7F0S-P3E1D=5%,5DY2=51K:FUH M9&L*U
F(WA!.VUW1T7D5C18,7V947H5K21-4J4A600E-%&HF(WA!.S%U240V9S,U=AL362E1D1F1P,"Q,MF5-/M-B1T1SHO,G
0.1#5#(B1-93DK51,33)H*UA,3%IV4U04E)H<6,E0F M-2M-SA+>2MT65@+K+T\$A6UDF(WA!.S@Q,C%J2&-0-5AV,VUE95--F-2,6QK15-7-E1R39%9)1VIQ
M-E-E,GA-#A13D-1V>2T10,4B@O7-E1U+8Q,VLX)B461R*V<4/E7H569-545U56Q8B-FI31D1V&A,1UH#,THD
M,V10,S-3C&1C,V1/4#4P5C1V2C%"6\$(WA!.W1,W50,%\$F,F94J9D179V9L M="#14Y6%21U3TEK M9-15" M43F535A7>"W(FW!.TQ1-E7@V>E5X+V0-51Y=>51-3-
9=%Y,6U7,V15T30E=>M+DY#>5(F(WA!.VQ9-7913E%9%Z5D8A-%HOD=34-%B17A-5%WU3SAY&M#A14,X/#E2D17-GAD9F9Y997-X,&H04&S%F(WA!.M:W+WH+WI-
G8Y13%W+SI+SQ>-.9GDS=316,"MV-%X)E+>G1*EEK9&E&5G8 M0T96<35D<54K3#12UEZ4-4-&@O<640-8DEW

MH#1:E%3X0WYI=^AC|JMRY^OYBG_E|CJ|>|X>|W(K1\$76+C MZA@?YE_="|=|UL=3=K1\$4JW7,2PTW^|RY37E\$7^=(2BKMQ_*W^K%|IORB+_M/Q5VX_E,5^="|H|QD1\$1\$01GQQROR&|M<#/#FJT=53UM-44<|LDB<|AHU1UHH)=5,U"=5/\$(5D9<|W_H-WA_N-U3\$R-B%PU^8UVFJD|321Z, M3N2LX=X:5^="|H>O^=54IG_CQW+&Q+J-KG=5M<#7<|QMF1L5HZGD+(S6_M2I5YSP_L0V8RB1B823N|21D9SCBUPR>|T-B|MJDU3=93D^=PB%&+4J3UH+U8K0Z6NKKX^+>|N+56SM8QFEEA+L=3?|SDGS_M|(4Y30,D&|SUHH->TK4=DU-26G!:=(*.K<|&QU\$-R<|YWG!PSC.||"L=I MNT>XZ0U9,+=24%,72U\$+97M+7&5Q+W-W6\$||"ZCS5MQ%A16\$|HHH>TQJ?4 MM/07JZ;|MD^KM-||\$V;#HL%Q^+3X1?|FC|QY^T=|%J..J..A=|=V1_VQ6HDF|M=1+3,+9A=7=|FJ,C-R-MW/4>7>|F5RUIUQM%05N>|18+/>G2%&C(N)DC#L^OGGUX^+50EG*P|MQ(FA%R&N=QZ1TY35M=2%Q|JF<|BFH(SF0C)&ICD|WV|K9VWCHJW>8-JV_MU,VW<|F<|A>|3U|G>|Q^+41HRDKDN21>|A>|Z>|6V0GUVW92:FL<|\$PJ7QA_MC:E|K=G((1Q+&:N0N6T?78LT>H+3U%06UI,DH<|D^|>Y-6..M4QH2DKD.21-LLC(HWR20:R->+G.<<|HLV1,012U5P5+.R&5M+;|P^# US7D>G!Q\$1*|XCB-<|M6P4,-+325%&DK/Q55C^2/8X^&3<YH|LJ|>|90#&G8^A\$4,CU MW=ZK54FVM#VZGK+3A|W|HJ7S10|LC|G&0/>A@|JSH75^H=7+|FJ=6-EH|MBL+6H2=QYXY|R3S(ZN-*|IN960..|CSB3UQNUC5^P2BG;|VQFTD_3L MBW9VN^6QY,&C|Q)Q)=5_MNU7469K9+&U.SLD5(^9DL53N8I=SEIPYPSQ|1RY=|THT&Y|RT9I9,G| M3E)>|GIX^+Y97A MK6<<2>|XJ|KUJW/|NA%>|FM#|8US>FBA>=^,|X&30'K(&>*,8|Y>KEH9ME19K1+&INNXYZFDIM-OH-M^ZLR1,1+M^5T1=2QU-^%M4/|R0R|P|P|5IT^M=J-M,|J^L|8,VW556%YR2IK0/S@%OFX^16W*99M)O%QN>JEK+7>ODW*AO#^+/WMP6NQ>ZBT|7|S2TT|JZ20F7^=(D8<|9ZWJ4XQ4=10WW>|M04MC7^,|#3G|P|2YS66UVTY>|Y|ME19K0<|6,W*QP^#&N-W ML|)P|7),+G+9JAFH|P|7),/#-T,A_5<6,|J|>6-Y^G1^D|TQ>|QMDN%7M^|G|>N8QH0@|JR02>|WAV+25*^362=|DBS|V|L|P,74E5|321|,87GA|O|M%Q|ZYK>|HJ6,1A-NM|X215^&2<#>|\$GD^9PLZ>|=|TKDN|U-SS3,-95\$U&RGFH,E^W=3=|M3RD>="6GKQPR^5XV@3+=|I=NCMT=+<|J|W<|Q|N@|MX>|Z@|PSPNSM(2ZNV0735E%2NIK5\$|=|QON+P^>|1X1|6LG93|R|7JW8K6D|G917QQ|M^W?|CF23R<|5<|N|WV>|EU11^>|TH|M^>|MLY|J|>|!&8YN?>|FV3W|T7R7N7=SNE|T92,00N,C@|INNWAHEH|#Q/6%M24-|PSMD^1*|SPL|JVT|J|C|3WV51=|IBGON30>|OM|A+6<+0>|94N@|C@4\$|||M|D0H&VWVWJ#5UXMND1/|OBM5N451F25G5S,=@|L|H|G|CR+&|E|U|U#|H31#01|MB6|CB34S?_>|W|H/&|CT|4H|H,6Y|/6Y|=5J|IC43+,*26M|J|&|M|Z|0-\$1=R:<|SC|84C+Y0U|H|F|F|T|-|N|Z|X|O-5|43EYXK|X:#="|Y|/Q|MU+Z0203C^,|MN|P|B|N|8N|15|Z|R16|D0|Q|M|G|H|U+>|E|N|7,9|P^E|M^4OZ4P^X|>|X|>|Y|J|Q2A>|EHBH+|MRH/|UFS|09U!>|ZBV|15B|L5|9|Y|/M-T,R2>|X8Q|63LXMFZ|E6Z04EDU^5W|M|K|S|U@>|S|,MO,W>|C|0>|Q|F|P|P|Q|U^&B|M=&V^EGWZNWPU+*|EFXX=&7S%>|=&D|>&|5ZV97BALMVNS#1P|Y|GKY+F<|8F^U>|75RU,K11S,,S=|I|R|Z|FKZ="|W^2S7BU4XHV5|)W3PU|M#2=P\$,|)KFY(Y\$+>|IV|O|V|B|>|7>|V29KMG^5T|RT4^7|7MNS5>|3/G=|W|M^C|R=|PGFVW|B^"|"E,-<|-6N|T|K|H|U|6S6ZD=|TU2+&|%00M+|P|P2X|9|0M|)Q|Q>|8|T|C|E|LE|IM,4U74T|MUQHXY>|E|PT|F|R|L|S>|R<|8<|161|9|1|K|C0|NE|L|K|D|P|0|U|#|XP|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0<|X@>|16W|H|F|A|V|C|L|E|V|C|4|M|N|L|C|N|Z|A|M^>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|J|K|S|Z|L|K|9^>|I|U|D|9|F|U|P|X|P|X|C|X#^M|V|L|0|Q|U|W|Z|J|5=|-1|E|D|8|2|S|6|1|H|K|V@|Y|L|C|513>|A|75E&|Z|7|J|MH|H960="|SY|WB,D|D|BUABPJY5VN3|J|W1|G|2,2|1DZ|FJ|7Q%|5|X,>|3|N|M+|FL<|7<|=|CL^Y>|OM>|0|IVG+<|9|E|A|X|H|K|H|K|>|*|S|H|8|V|G|<|6|B|2>|I:5>|j|S|M-17|ET4Y|E|6|G|3|T|N|Z|N|Y@>|0|@|>|W|P>|>|B|S|C|M^A/-|7A|T^2-|L|D|G|U|4|S|P|H|G|H|U|>|E|8|G|X|1|77|ME|V|D|B|<|W|U|W|W="|P,<|U|R|I|X@>|2|A|0|>|I|G|B|N|U|K|Y|/|K|&|V|H|K|C|6,1|>|D|J|5|D|5|J|B|5|N|Z|A|0|>|6|C|3|8|B@>|@|C|1|0|+|4|N|+|5|W|3|V|7|5|H|A|3|Y|V|M|>|S|G|I|Q|D|B|12|N=&>|K|A|E|O|H|Y|>|H|J|S|6|0+|D|S|*|U|W|S|Q|E|G|Y|H|U|M|9|9|H|W|Y|Z|B|W|H|K|B|Z|C|Z?_>|0|9|S|3|3-|8|X|=|N|S^>|V|3|V^|P|R|3|5|T|H|B|W|7^4S+56|V|P|U|7|2|1|O|H|9|L|J|+|O|+|B|T|B|Y|M^#|M|Z|U|B|*|16|P,&N|5|G|T|W|6|U|W|U|

